Form 8-K - Current report:
SEC Accession No. 0001104659-25-057308
Filing Date
2025-06-06
Accepted
2025-06-06 16:05:24
Documents
13
Period of Report
2025-06-03
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2517225d1_8k.htm   iXBRL 8-K 29031
2 EXHIBIT 16.1 tm2517225d1_ex16-1.htm EX-16.1 2510
  Complete submission text file 0001104659-25-057308.txt   199334

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sls-20250603.xsd EX-101.SCH 3041
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sls-20250603_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sls-20250603_pre.xml EX-101.PRE 22377
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2517225d1_8k_htm.xml XML 3688
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33958 | Film No.: 251030552
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)